Phenotyping of COPD and other destructive lung diseases

  • Research type

    Research Study

  • Full title

    Phenotyping of Chronic Obstructive Pulmonary Disease (COPD) and other destructive lung diseases

  • IRAS ID

    203713

  • Contact name

    Simon Johnson

  • Contact email

    simon.johnson@nottingham.ac.uk

  • Sponsor organisation

    University of Nottingham

  • Duration of Study in the UK

    4 years, 11 months, 29 days

  • Research summary

    Chronic Obstructive Pulmonary Disease (COPD) is the third most common cause of death world wide. COPD is a complex collection of conditions, all share the feature of limited expiratory air flow but patients are heterogeneous(widely different) in their prognosis and response to treatment with specific manifestations in different individuals(endotypes).Specific endotypes include, emphysema, chronic bronchitis, stable disease, increased loss of lung function, exacerbations and cardiovascular morbidity.
    Many of these factors are unidentified at the present time and patients are treated with the same type of therapies. If we are able to ‘group’ or ‘endotytpe’ patients by using specific markers of disease (biomarkers ) recently identified from another study will help us tailor patient treatment reduce medication side effects and costs.In addition to COPD , we will also include a number of other destructive lung diseases in this study which share a similar disease process
    (including lymphangioleiomyomatosis, Langerhans Cell Histiocytosis, Birt Hogg Dubé disease and others).

  • REC name

    East Midlands - Nottingham 2 Research Ethics Committee

  • REC reference

    17/EM/0109

  • Date of REC Opinion

    3 Apr 2017

  • REC opinion

    Favourable Opinion